AI-immunology Corporate Presentation January 2021
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
AI-immunology™
C o r p o r a t e P r e s e nt a t i on
Ja nu a r y 2 0 2 1
© Ev ax i on Bi otec h A/S. Al l r i ghts r es er v ed w or l dw i de. C openhagen, D enm ar k , 2021. | 1
Forward-Looking Statements
This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this
presentation, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of
management and expected market growth are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “hope,” “intend,” “may,”
“might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-
looking statements contain these identifying words. These statements are only predictions based on our current expectations and projections about future events. There are
important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or
achievements expressed or implied by the forward-looking statements, including risks and uncertainties relating to: the implementation of our business model and our plans to
develop and commercialize our lead product candidates and other product candidates, including the potential benefits thereof; our ongoing and future clinical trials for our lead
product candidates, whether conducted by us or by any of our collaborators and partners, including the timing of initiation of these trials and of the anticipated results; our pre-
clinical studies and future clinical trials for our other product candidates and our research and development programs, whether conducted by us or by any of our collaborators and
partners, including the timing of initiation of these trials and of the anticipated results; the timing of and our ability to obtain and maintain regulatory and marketing approvals for
our product candidates; the rate and degree of market acceptance and clinical utility of any products for which we receive marketing approval; the pricing and reimbursement of
our product candidates, if approved; our ability to retain the continued service of our key employees and to identify, hire and retain additional qualified employees; our
commercialization, marketing and manufacturing capabilities and strategy; our intellectual property position and strategy and the scope of protection we are able to establish and
maintain for the intellectual property rights covering our product candidates and technology; our ability to identify and develop additional product candidates and technologies with
significant commercial potential; our plans and ability to enter into collaborations or strategic partnerships for the development and commercialization of our product candidates;
the potential benefits of any future collaboration or strategic partnerships; our expectations related to the use of proceeds from this offering and our existing cash, cash
equivalents and marketable securities; our financial performance, including our estimates regarding expenses, future revenue, capital requirements and needs for additional
financing; developments relating to our competitors and our industry; the impact of government laws and regulations; and our expectations regarding the time during which we will
be an emerging growth company under the JOBS Act; the impact of being a Foreign Private Issuer and the impact of the pandemic caused by the novel coronavirus known as
COVID-19.
© Ev ax i on Bi otec h A/S. Al l r i ghts r es er v ed w or l dw i de. C openhagen, D enm ar k , 2021. | 2
Disclaimer
Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or
achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. Except as
required by law, we are under no duty to update any of these forward-looking statements after the date of this presentation to conform our prior statements to actual results or
revised expectations.
This presentation includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties
or us. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although
they do not guarantee the accuracy or completeness of such information. All of the market data used in this presentation involves a number of assumptions and limitations, and
you are cautioned not to give undue weight to such estimates. While we believe these industry publications and third-party research, surveys and studies are reliable, we have not
independently verified such data. The industry in which we operate is subject to a high degree of uncertainty, change and risk due to a variety of factors, which could cause
results to differ materially from those expressed in the estimates made by the independent parties and by us.
This presentation is solely for the information of the recipients and may not be used, reproduced or distributed without the consent of the Company, except that you may, without
the Company's consent, share an original copy of this presentation with other members of your organization who you deem have a valid business reason for reviewing it. By
accepting this presentation, you acknowledge that you are solely responsible for your own assessment of the Company and that you will conduct your own analysis and be solely
responsible for forming your own view of the potential future performance of the Company's business.
© Ev ax i on Bi otec h A/S. Al l r i ghts r es er v ed w or l dw i de. C openhagen, D enm ar k , 2021. | 3
Offering Summary
Issuer Evaxion Biotech A/S
Proposed Symbol / Exchange EVAX / Nasdaq CM
Deal Type IPO
Estimated Offering Size $30 million
Over-Allotment Option 15%
Securities Offered American Depository Shares (100% Primary)
Development of pipeline candidates including lead programs EVX-
Use of Proceeds 01, EVX-02 and EVX-B1, enhancement of proprietary platform
technologies and general corporate purposes
Sole Bookrunner Oppenheimer & Co.
Lead Manager Ladenburg Thalmann
© Ev ax i on Bi otec h A/S. Al l r i ghts r es er v ed w or l dw i de. C openhagen, D enm ar k , 2021. | 4
Evaxion Aspires to Become a World Leader in AI-Immunology, Decoding the
Human Immune System, to Develop Effective Immunotherapies Based on
Deep Biological Insights
Immune system Artificial Intelligence Immunotherapies
©©Ev
Evax
axi on
i onBiBiotec
otechhA/S.
A/S.AlAll lr ri ghts
i ghtsr res
eserervved
edwwororl dw
l dwi de.
i de.CCopenhagen,
openhagen,DDenm
enmararkk, ,2021.
2020 || 55
Investment Highlights
Ground-breaking AI-immunology Identification and development of multiple Poised for rapid growth with
platforms to enable rapid and candidates to validate our AI-immunology experienced management team,
scalable discovery and development platforms strong IP portfolio and scalable
of immunotherapies business model
3 proprietary AI-immunology platforms that simulate • Early clinical results with lead product • Highly experienced executive management
the human immune system candidate EVX-01 in combination with team with deep expertise in drug development
checkpoint inhibitor (CPI) therapy
• PIONEER™ platform for the identification of and Artificial Intelligence
patient-specific neoepitopes to potentially • Near-term Phase 1/2a readouts for lead • Strong IP portfolio with 8 issued patents and 46
transform the immuno-oncology treatment immuno-oncology product candidates EVX-01
pending patent applications
landscape and EVX-02 in first half of 2021
• Numerous opportunities for rapid pipeline
• EDEN™ platform for the identification of • Additional oncology product candidate EVX-03
expansion and partnerships
broadly protective antigens for use against and S. aureus vaccine product candidate
bacterial diseases EVX-B1 in preclinical development
• RAVEN™ platform for the rapid response to
future pandemic viral diseases
© Ev ax i on Bi otec h A/S. Al l r i ghts r es er v ed w or l dw i de. C openhagen, D enm ar k , 2021. | 6
The Evaxion Executive Management Team
Experienced executive management team with proven ability to execute within AI-immunology, drug development and
business operations
Chief Executive Officer Chief Financial Officer Chief Business Officer Chief Innovation Officer Chief Medical Officer
Lars Staal Wegner, MD Glenn S. Vraniak Niels Møller, MD Andreas Mattsson Eric Heegaard, MD, PhD
© Ev ax i on Bi otec h A/S. Al l r i ghts r es er v ed w or l dw i de. C openhagen, D enm ar k , 2021. | 7
ADVISORS
BOARD OF DIRECTORS
Science and Drug Development Business and Stakeholders
Marianne Søgaard, Chair of the Board Jeffrey S. Weber, MD, PhD Christian Schilling, MD, PhD
Served for 22 years at the Kammeradvokaten/Law Firm Professor of Oncology and the Deputy Director of Perlmutter, Responsible for the Global Therapeutic Areas in Human
Poul Schmith as a corporate lawyer, partner and board Co-Director of Melanoma Program at the New York University Pharma at Boehringer Ingelheim for many years. A member
member. Served on various boards and joined Evaxion (NYU)-Langone Cancer Center and Head of Experimental of the Human Pharma Executive Board and Co-Chair of the
from 2018 to 2020 as an executive, corporate lawyer and Therapeutics at NYU Langone Medical Center LLC. Global Licensing Committee representing the Human Pharma
legal advisor to the company. Guido Grandi, PhD Business Unit.
Steven Projan, PhD Professor in Biochemistry and Biotechnology extensive Andy Weber
Former Sr V.P. R&D and Head of Infectious Disease & experience in the vaccine industry, working several years at US Federal Government, Deputy Coordinator for Ebola
Vaccines at MedImmune, successfully led four programs Novartis’ Vaccines & Diagnostics Division VP of Research. A Response at the U.S. Department of State, former Assistant
resulting in the approval of novel anti-infective drugs. key person in the development of Bexsero. Secretary of Defense for Nuclear, Chemical, and Biological
Roberto Prego Pineda Anthony Purcell, PhD Defense Programs, advisor for Threat Reduction Policy in the
office of the Secretary of Defense.
Cocrystal Pharma, IVAX and TEVA, and as an investor in Leader in the field on ligand/MHC binding mass spec. NHMRC
biotech companies. Principal Research Fellow and Deputy Head (Research) of the
Robert J. Palay, JD, MB
Department of Biochemistry at Monash University. Chairman of Tactics II Equity LLC, V.P. of multiple entities
JoAnn A. Suzich, PhD
specializing in life science investments. Founder or early-
Head of Infectious Disease & Vaccines, Corporate Michael W. Washabaugh, PhD
stage investor in genomics and stem cell-based companies.
Leadership Team at MedImmune. A global leader for therapeutic protein & vaccine development.
Previous positions in Adello Biologics (CSO), MedImmunne
Rajeev Surati, PhD
Helen M. Boudreau, MBA
(Senior Director, Research & Development), Merck & Co Inc. Investor and serial entrepreneur in technology and science.
Served as CFO for NASDAQ listed Proteostasis
(Senior Director, Head of Biologics and Vaccine Analytical Built several successful companies, Data Science Mentor at
Therapeutics and privately held FORMA Therapeutics.
Science) and has supported several launched products. Harvard Medical School.
Spent 16 years in senior finance and strategy roles at
Søren Brunak, Dr. phil., Ph.D., Professor Tom Wylonis, PhD
Novartis and Pfizer, including global CFO Oncology
business unit, CFO US Corporate. Rated as one of the Worlds 200 most influential biology and Chairman of the Board of Evaxion from 2015 to 2020. Investor
biochemistry scientists and a member of the Nobel Award and board member of several life science companies. Former
Panel. Professor of Bioinformatics at the Technical University of Global Director at McKinsey & Company.
Denmark and professor of Disease Systems Biology at the
University of Copenhagen and founding Director of the Center
for Biological Sequence Analysis.
© Ev ax i on Bi otec h A/S. Al l r i ghts r es er v ed w or l dw i de. C openhagen, D enm ar k , 2021. | 8
We are Using AI to Decode the Immune System, with Potential to Lead to
Effective Immunotherapies
Immune system Artificial Intelligence Immunotherapies
The immune system is nature’s AI and data are key to decoding the AI translates data into
strongest weapon against diseases immune system immunotherapies
• When the immune system is engaged, people • Our predictive power relies on our ability to • Using AI, we are able to rapidly discover and
are often able to entirely eliminate a disease or process and interpret vast amounts of high- develop potentially effective drug candidates
infection from the body quality data
• Our AI models allow us to identify unique drug
• Our AI models mimic the human immune system • We transform the data into advanced algorithms targets which may translate into a higher
in silico in order to predict whether the body will that predict cellular interactions within the likelihood of clinical success
have an immune response to certain stimuli immune system and identify novel therapeutic
targets that stimulate an immune response
© Ev ax i on Bi otec h A/S. Al l r i ghts r es er v ed w or l dw i de. C openhagen, D enm ar k , 2021. | 9
AI-immunology™ Core Technology Currently at Work in Several Therapeutic
Areas and Potentially Deployable in Many More
Immune system Artificial Intelligence Immunotherapies
© Ev ax i on Bi otec h A/S. Al l r i ghts r es er v ed w or l dw i de. C openhagen, D enm ar k , 2021. | 10Advancing a Robust Immunotherapy Pipeline to Validate our AI-Immunology
Platform Technologies
Stage of Development
Product Candidate Key Upcoming
AI platform
(Delivery modality) Milestone
Pre-clinical Phase 1 Phase 2 Phase 3
EVX-01
(Liposomal/Peptide)
First Half 2021:
Metastatic Melanoma, NSCLC, Bladder Cancer 2a
Phase 1/2a readout
PIONEERTM EVX-02
(DNA)
Patient-specific
First Half 2021:
cancer Adjuvant Melanoma 2a
Phase 1/2a readout
immunotherapies
EVX-03
(Targeted DNA)
Second Half 2021:
Multiple Cancers
Regulatory filing
EVX-B1
EDENTM (Adjuvanted Recombinant Proteins)
Vaccines against Second Half 2022:
bacterial diseases S. aureus, SSTI Regulatory (IND) filing
© Ev ax i on Bi otec h A/S. Al l r i ghts r es er v ed w or l dw i de. C openhagen, D enm ar k , 2021. | 11Validating Our AI-immunology Platforms by Developing Our Current Pipeline
of Product Candidates through Phase 2b PoC before Out-licensing
AI-immunology Delivery Modality Product Candidates Out-licensing
Platforms
Peptides EVX-01
PIONEER™
Proteins EVX-02 Clinical PoC
EDEN™
DNA EVX-03
RAVEN™
mRNA EVX-B1
Accelerating drug discovery and development, utilizing AI platforms to expand our portfolio and pursue earlier
out-licensing arrangements
© Ev ax i on Bi otec h A/S. Al l r i ghts r es er v ed w or l dw i de. C openhagen, D enm ar k , 2021. | 12A I I M M U N O - ONCO LO GY
P L AT F O R M
© Ev ax i on Bi otec h A/S. Al l r i ghts r es er v ed w or l dw i de. C openhagen, D enm ar k , 2021 | 13PIONEER: Proprietary AI Platform for the Rapid Discovery and Design of
Patient-Specific Neoepitopes used to Derive Immuno-Oncology Therapies
T-cell Neoepitopes are ideal cancer immunotherapy targets that:
• arise from patient-specific tumor mutations;
• play a critical role in T-cell mediated antitumor immune response;
• are absent from normal tissues and;
• are recognized as non-self by the immune system.
Our proprietary AI-platform PIONEER is trained to efficiently
identify and select the best neoepitopes for de novo T cell
induction and antitumor effect in each patient
Neoepitope
recognition
© Ev ax i on Bi otec h A/S. Al l r i ghts r es er v ed w or l dw i de. C openhagen, D enm ar k , 2021 | 14Our PIONEER Process Providing Patient-Specific
Therapies to Patients
1.
Tumor and normal We have demonstrated in the EVX-01 Phase 1/2a clinical trial
tissue samples
that PIONEER-predicted neoepitopes induce specific T cells in
100% of patients. 80.5% of the administered neoepitopes
induced reactive T cells in patients, of which 84.8% were de
novo responses.
4.
Combination 2.
therapy with DNA sequence
We believe that PIONEER’s state-of-the-art performance is due
check-point of tumor and
inhibitors healthy tissue to our deep biological understanding and the ability of our AI
technologies to decode the immune system
We have already demonstrated that we can deliver AI-identified
cancer immunotherapies to patients in as little as 7 weeks after
3.
Cancer neoepitopes collection of patient specific biopsies
identified by PIONEER
© Ev ax i on Bi otec h A/S. Al l r i ghts r es er v ed w or l dw i de. C openhagen, D enm ar k , 2021 | 15PIONEER Decodes the Biological Processes Leading to an
Antitumor Effect
1. Mutation 2. Expression 3. Translation 4. Presentation on MHC class I 5. T cell response 6. Clonal neoepitopes
and class II
T cell
TCR
MHC
Tumor cell
10
Avg. Hits in 10 Best-ranked Neoepitopes
Improved prediction of
8 8.7 PIONEER outperforms
neoepitopes directly
state-of-the-art public
translates into enhanced
tools for neoepitope
6 antitumor effect in
identification
preclinical studies
4
2 2.6
0
Public
©
© Ev
Evax
axii on
on Bi
Bi otec
otechh A/S.
A/S. Al
Al ll rr ii ghts
ghts rr es
eser
er vved
ed w
w or
or ll dw
dw ii de.
de. C
C openhagen,
openhagen, D
D enm
enm ar
ar kk,, 2020
2021 || 16
16Key Advantages of Our PIONEER Platform
● Identification of Therapeutic Neoepitopes: Better anti-tumor effect correlating with de
novo T-cell activation
● Identification of Therapeutic Patient-Specific Neoepitopes: Unique to each patient’s
cancer based on HLA subtype
● Identification of Multiple Neoepitopes: Increase therapeutic effect and overcome clonal
heterogeneity and tumor immune escape issues
● Speed: Identifies neoepitopes within 24 hours from receipt of patient biopsy sequencing
data
● World Wide Clinical Applicability: In accordance with GAMP5 and compliant with cGMP
● Potential for Repeat Use of PIONEER Over the Lifetime of a Patient’s Cancer
Treatment: Multiple, PIONEER-designed therapies targeting emerging cancer clones
● Safety Profile: Deselects potentially harmful neoepitopes, limiting off target effects
● Continuous Improvement: Incorporates ongoing data and new features to increase
predictive power
© Ev ax i on Bi otec h A/S. Al l r i ghts r es er v ed w or l dw i de. C openhagen, D enm ar k , 2021. | 17Screening Multiple Delivery Modalities
and Moving the Most Promising Into the Clinic
We select the optimal delivery modality for each of our PIONEER derived candidates to maximize their potential
Evaxion performs broad preclinical screening
CD4+ CD8+ Manufacturing Manufacturing
Delivery Modality
response response time cost
Peptide/liposomal (EVX-01) +++ ++ 7 weeks Low/Medium
DNA (EVX-02) +++ +++ 10-12 weeks Medium
Reactive
C CD4+ T cells
%IFN & TNF⍺ of CD4+ T cells
0.5
Targeted DNA (EVX-03) +++ ++++ 10-12 weeks Medium 0.4
0.3
0.2
0.1
0.0
© Ev ax i on Bi otec h A/S. Al l r i ghts r es er v ed w or l dw i de. C openhagen, D enm ar k , 2021. | 18EVX-01 Phase 1/2a Clinical Trial Design
Readout anticipated in first half of 2021
Part 1: Dose escalation
Objectives
EVX-01 + PD-1/PD-L1
Primary: Safety and tolerability
Secondary: Immunogenicity and feasibility of manufacturing
Dose level 1: 500 μg total peptide, n=6
Tertiary: Objective response (OR), progression free survival (PFS) and overall
survival (OS)
Dose level 2: 1000 μg total peptide, n=3
Indications Dose level 3: 2000 μg total peptide, n=3
Advanced or metastatic cancers: Melanoma, NSCLC, Bladder
Treatment Part 2: Recommended dose
EVX-01 inj. biweekly 3 x intraperitoneal 3 x intramuscular plus
pembrolizumab every 3 weeks or nivolumab every 2 weeks EVX-01 + PD-1/PD-L1
Optimal dose, n=13
Readout anticipated first half of 2021
© Ev ax i on Bi otec h A/S. Al l r i ghts r es er v ed w or l dw i de. C openhagen, D enm ar k , 2021. | 19Preliminary Data From EVX-01 Phase 1/2a Clinical Trial
Key findings to date, n=5 Patients
Immunogenicity
• 100% of patients had reactive T cells
• 80.5% of the administered neoepitopes
induced reactive T cells in patients, of which
84.8% were de novo responses
Clinical benefit in 3 of 5 patients
• One complete response (CR)
• Two partial responses (PR)
Safety
Clinical data from five patients treated on dose level 1 of EVX-01 in combination with PD-1 CPI.
Patients were monitored during the clinical trial and disease development was determined by measuring and
EVX-01 appears to be well-tolerated with only scoring development of tumor lesions according to the international acknowledged RECIST criteria.
mild Grade 1 adverse events observed Black triangles indicate time of treatment with EVX-01.
© Ev ax i on Bi otec h A/S. Al l r i ghts r es er v ed w or l dw i de. C openhagen, D enm ar k , 2021. | 20EVX-02: Our DNA-based Immunotherapy for the Adjuvant Treatment of
Melanoma
PIONEER-predicted neoepitopes using our DNA delivery modality lead to enhanced antitumor effects in pre-clinical mouse studies
Α. Tumor Volume EVX-02 induces robust, dose- EVX-02 induces neoepitope-recognizing circulating
Following Inoculation dependent antitumor immunity in CD8+ T cells and neoepitope-reactive CD4+ and
a tumor mouse study CD8+ T cells in a tumor mouse study
P-values were calculated using unpaired t test with Welch’s correction.
Figure A: PEVX-02 Phase 1/2a Clinical Trial Design
Preliminary data readout expected first half of 2021
Objectives
Primary: Safety / tolerability and immunogenicity Part 1: Delivery modality assessed
Secondary: Relapse free survival at 12 months
EVX-02A (polymer)
plus nivolumab, n=8
Indications
Adjuvant therapy after complete resection of Stage IIIB/IIIC/IIID
EVX-02B (jet injector device)
or Stage 4 melanoma in patients with high risk for recurrence plus nivolumab, n=8
Status
5 patients recruited
Treatment Preliminary data
EVX-02 inj. 8x intramuscular every 2 weeks plus readout expected
anti-PD-1 nivolumab every 4 weeks Part 2: Expansion cohort first half of 2021
N=24-30
EVX-02 with Optimal Delivery Methodology
© Ev ax i on Bi otec h A/S. Al l r i ghts r es er v ed w or l dw i de. C openhagen, D enm ar k , 2021. | 22EVX-03: Our Targeted DNA-based Immunotherapy for the Treatment
of Various Cancers
PIONEER-predicted neoepitopes using our targeted DNA delivery modality lead to enhanced antitumor effects in preclinical mouse studies
Proprietary APC targeting EVX-03 compound Antitumor effect CD4+ and CD8+ T cells
The majority of mice treated with EVX-03 had complete Higher levels of neoepitope-reactive T cells were
tumor eradication compared to mice treated without a observed in mice being treated with EVX-03 compared to
targeting unit in a tumor mouse study mice immunized without a targeting unit in a tumor mouse
study
P-values were calculated using non-parametric Kruskal-Wallis
with Dunn’s multiple comparison corrections (*pA I B A C T E R I AL VA C C I NE
P L AT F O R M
© Ev ax i on Bi otec h A/S. Al l r i ghts r es er v ed w or l dw i de. C openhagen, D enm ar k , 2021 | 24EDEN: AI Platform for Rapid Identification of Highly Protective Antigens
for use in Prophylactic Vaccines Against Bacteria
RECOGNIZES
SHARED
FEATURES
Novel vaccine antigens with high precision: Trained on our own curated data:
Proprietary algorithms that allow for prediction with great precision of To identify the truly protective and non-protective antigens validated
antigens that will trigger a robust protective immune response against in human and animal models
almost any bacterial infectious disease
Proprietary technology: Pre-clinically validated in seven different pathogens:
Proprietary machine learning ensemble of AI models used to interpret We intend to develop a pipeline of vaccine candidates using this
immunological-relevant information in relation to bacterial antigens platform
that incur protection in a vaccine setting
©
© Ev
Evax
axii on
on Bi
Bi otec
otechh A/S.
A/S. Al
Al ll rr ii ghts
ghts rr es
eser
er vved
ed w
w or
or ll dw
dw ii de.
de. C
C openhagen,
openhagen, D
D enm
enm ar
ar kk,, 2020
2021 || 25
25Within 48 Hours, EDEN is Able to Identify Novel and Highly Protective
Vaccine Antigens Against Bacterial Diseases
Step 1 Step 2 Step 3 Step 4 Step 5
Isolation and sequencing Prepare pathogen Discriminate protective Antigen selection and Process antigen through
of the target pathogen proteome from non-protective design pre-clinical development
antigens pipeline
● EDEN utilizes ● Protein coding regions ● EDEN identifies unique ● Only a few dozen ● Antigen candidates
proteomes from of such strains are feature combinations candidate antigens are produced in high
clinically relevant translated into amino identified from a whole quality and processed
bacterial strains as acid sequences ● EDEN predicts bacterial proteome are through a pre-clinical
inputs previously untested left to be tested development pipeline
proteins, scoring each experientially for in vivo confirmation
of them from 0 to 1 for
their probability of ● EDEN optimizes the
eliciting a protective design of identified
immune response vaccine antigens
© Ev ax i on Bi otec h A/S. Al l r i ghts r es er v ed w or l dw i de. C openhagen, D enm ar k , 2021. | 26EVX-B1: Our Prophylactic Vaccine for the Prevention of S. aureus
There were ~119,000 S. aureus bloodstream infections with ~20,000 deaths Our proprietary toxoid fusion
in 2017. Part 1: Delivery modality assessed protein provides 100%
protection in peritonitis
Economic impact of MRSA on U.S. hospitals alone is estimated to be $3.2 - models and skin abscess
$4.2bn models of infection using two
different challenge strains
No prophylactic vaccine for the prevention of S. aureus infections has
received marketing authorization to date
p-value 0.0001***, calculated using Log-rank Mantel-Cox test.
EVX-B1 is a multicomponent vaccine product candidate:
Our COMBO vaccine tested
• Novel, protective, EDEN-identified vaccine antigens evaluated in
with two different adjuvant
pre-clinical protection and challenge studies and in functional systems induces clearly
assays. significant protection in a
preclinical S. aureus USA300
• Uniquely designed toxins selected from a long list of relevant toxins abscess challenge model
and pre-clinically evaluated as single proteins and chimerics.
• Adjuvant selected based on pre-clinical tests and optimal profile for
clinical indication.
P-valueKey Strengths of our EDEN Platform Enabling AI-Based Vaccine
Discovery and Design
● Ability to Predict Protective Vaccine Antigens: Predicts protective vaccine antigens with great
precision, potentially improving on the attrition rates for new vaccine product candidates
● Identification of Novel and Unbiased Targets: Identifies underlying feature patterns enabling discovery
of novel vaccine targets
● Data Driven Precision: AI-based identification of novel targets and filters irrelevant proteins reducing
burden on pre-clinical development
● Ability to Provide Broad Protection: Leverages genomic sequencing data to identify targets or
domains present in clinical strains
● Extraordinary Sensitivity: EDEN is capable of identifying antigens included in marketed vaccines as
well as novel, protective antigens
● Speed: Completes antigen discovery in as little as 48 hours and identifies vaccine candidates in weeks
● Scalability: Can be applied in the discovery of vaccine candidates in almost any bacterial infectious
disease
© Ev ax i on Bi otec h A/S. Al l r i ghts r es er v ed w or l dw i de. C openhagen, D enm ar k , 2021. | 28A I VI R A L VA C C I NE
P L AT F O R M
© Ev ax i on Bi otec h A/S. Al l r i ghts r es er v ed w or l dw i de. C openhagen, D enm ar k , 2021 | 29RAVEN:
Rapid Response Platform for Viral Diseases
RAVEN addresses critical aspects of vaccine design:
The RAVEN platform can address
Combines elements from both PIONEERPart 1: Delivery
and modality
EDEN to produce assessed
vaccine designs that induce both a T-cell and
the public health threat posed by
B-cell response to viral diseases, which is believed to be critical to prevent infection by corona viruses
viral diseases in two key areas:
1. The need to act fast when the next Neutralizing focus High population coverage Novel T-cell and B-cell vaccine
coronavirus or a mutated COVID-
19 virus emerges. RAVEN may Minimal spike protein construct AI-driven identification of Seamless integration of T- and B-
allow for vaccines for human use for generation of neutralizing promiscuous T-cell (CD4+ and cell components into an adaptable
in, initially, less than 11 weeks. antibodies CD8+) epitopes from multiple design
proteins
2. The need for a viral platform that
can address other unmet medical
needs in viral diseases such as
respiratory syncytial virus and
cytomegalovirus. +
© Ev ax i on Bi otec h A/S. Al l r i ghts r es er v ed w or l dw i de. C openhagen, D enm ar k , 2021. | 30I N VE S T M E N T HI G HL I G HT S
© Ev ax i on Bi otec h A/S. Al l r i ghts r es er v ed w or l dw i de. C openhagen, D enm ar k , 2021 | 31Upcoming Milestones
H1 2021 EVX-01: Phase 1/2a readout and potential decision to move into a Phase 2b
H1 2021 EVX-02: Phase 1/2a readout and potential decision to move into a Phase 2b
H2 2021 EVX-03: Initiation of toxicology studies and submission of regulatory filing
H2 2022 EVX-B1: Assessment of final formulation and IND filing
© Ev ax i on Bi otec h A/S. Al l r i ghts r es er v ed w or l dw i de. C openhagen, D enm ar k , 2021. | 32Investment Highlights
Ground-breaking AI-immunology Identification and development of multiple Poised for rapid growth with
platforms to enable rapid and candidates to validate our AI-immunology experienced management team,
scalable discovery and development platforms strong IP portfolio and scalable
of immunotherapies business model
3 proprietary AI-immunology platforms that simulate • Early clinical results with lead product • Highly experienced executive management
the human immune system candidate EVX-01 in combination with team with deep expertise in drug development
checkpoint inhibitor (CPI) therapy
• PIONEER™ platform for the identification of and Artificial Intelligence
patient-specific neoepitopes to potentially • Near-term Phase 1/2a readouts for lead • Strong IP portfolio with 8 issued patents and 46
transform the immuno-oncology treatment immuno-oncology product candidates EVX-01
pending patent applications
landscape and EVX-02 in first half of 2021
• Numerous opportunities for rapid pipeline
• EDEN™ platform for the identification of • Additional oncology product candidate EVX-03
expansion and partnerships
broadly protective antigens for use against and S. aureus vaccine product candidate
bacterial diseases EVX-B1 in preclinical development
• RAVEN™ platform for the rapid response to
future pandemic viral diseases
© Ev ax i on Bi otec h A/S. Al l r i ghts r es er v ed w or l dw i de. C openhagen, D enm ar k , 2021. | 33You can also read
